NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment right up until illness progression or the individuals are unable to tolerate the study drugs.- "Our study revealed the crucial role of the KLF16/MYC regulatory axis in modulating tumor develop